Drug Couponing: Better or Worse for Biosimilars?
Payers will have to carefully mull limited options.
Indication-Specific Pricing and Biosimilars
Value-based health care has forced several systemic changes.
Mylan Files Application for First Herceptin® Biosimilar
Two Reminders in Biosimilar Discussions
Sometimes the actual study results are less the point than the objectives of the investigators.
Switching and Discontinuations for Remicade and Its Biosimilar in Turkey
Enthusiasm dulled for new US biosimilar Inflectra for Rheumatoid Arthritis.
Can Physician Prescribing of Biosimilars Be Influenced by Price?
New study in a small sample of physicians implies cost factor could be a big influence.
Value-Based Contracting: What's the Industry Risk-Benefit?
Gaining rapid uptake for biosimilar products is a challenge for manufacturers and payers.
